The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

This was the stock's second consecutive day of losses.

In that report, analysts expect Vertex Pharmaceuticals to post earnings of $4.11 per share. This would mark year-over-year growth of 0.74 ... Based on our research, we believe these estimate ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not ...

We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds. In this article, we are ...

Vertex Pharmaceuticals Incorporated (VRTX) stock saw a modest uptick, ending the day at $485.37 which represents a slight increase of $6.72 or 1.40% from the prior close of $478.65. The stock opened ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has ... expansion to younger age groups should drive CF sales growth, the potential launch of Vertex’s fifth CFTR modulator therapy, vanza ...

Vertex Pharmaceuticals, best known for its breakthrough ... Vertex's executive vice president, Global Research and chief scientific officer. "As a company founded on innovative science, we're ...

Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Inc., Union Pacific Corp. and Vertex Pharmaceuticals ... in new growth avenues and competitive ...

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.